Parotitis primary prevention

Revision as of 18:38, 18 September 2017 by WikiBot (talk | contribs) (Changes made per Mahshid's request)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Parotitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Parotitis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT or MRI

Treatment

Medical Therapy

Surgery

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Parotitis primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Parotitis primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Parotitis primary prevention

CDC on Parotitis primary prevention

Parotitis primary prevention in the news

Blogs on Parotitis primary prevention

Directions to Hospitals Treating Parotitis

Risk calculators and risk factors for Parotitis primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Luke Rusowicz-Orazem, B.S.

Overview

Effective preventative measures for parotitis include the mumps vaccine, maintaining personal hygiene and limiting proximal contact with mumps or staphyloccocus aureus infected individuals, limiting sexual contact with HIV-infected individuals and using condoms during sexual intercourse, and the Bacillus Calmette-Guérin vaccine to prevent extrapulmonary tuberculosis. Preventative measures for obstruction-based parotitis include reducing risk factors for salivary gland stones and parotid gland neoplasia.

Prevention

Infectious parotitis

  • Administering the mumps vaccine
    • 78% effective at a single dose; 88% effective with two doses administered with at least 28 days in between.[1]
  • Personal hygiene and limiting contact exposure:[2]
  • Limiting contact with children between 9 months and 15 years old.[1]
  • Limiting sexual contact with HIV-infected individuals and using condoms.[3]
  • Administering the Bacillus Calmette-Guérin vaccine to prevent tuberculosis.[4]

Obstructive parotitis

  • Reducing risk factors associated with salivary gland stones or neoplasia:
    • Limiting alcohol consumption.
    • Reducing tobacco consumption and smoking.
    • Avoiding harmful inhalants, such as pesticides.

References

  1. 1.0 1.1 "Mumps | Vaccination | CDC".
  2. "Mumps | Transmission | CDC".
  3. "Prevention | HIV Basics | HIV/AIDS | CDC".
  4. "apps.who.int" (PDF).

Template:WH Template:WS